Yr Athro Andrew Tee

2022

• Gampala, S. et al. 2022. Correction: Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. British Journal of Cancer 127(7) (10.1038/s41416-022-01938-9)

2021

• Zhang, L. et al. 2021. The role of mitochondria-linked fatty-acid uptake-driven adipogenesis in Graves’ Orbitopathy. Endocrinology 162(12), article number: bqab188. (10.1210/endocr/bqab188)
• Vinsland, E. et al. 2021. The zinc finger/RING domain protein Unkempt regulates cognitive flexibility. Scientific Reports 11(1), article number: 16299. (10.1038/s41598-021-95286-y)
• Gampala, S. et al. 2021. Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. British Journal of Cancer 124(9), pp. 1566–1580. (10.1038/s41416-021-01270-8)
• Xie, J. et al. 2021. Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis. Cellular and Molecular Life Sciences 78(1), pp. 249–270. (10.1007/s00018-020-03491-1)

2020

• Zhang, L. et al. 2020. Distinctive features of orbital adipose tissue (OAT) in Graves' orbitopathy. International Journal of Molecular Sciences 21(23), article number: 9145. (10.3390/ijms21239145)

2019

• McEneaney, L. J. and Tee, A. R. 2019. Finding a cure for tuberous sclerosis complex: from genetics through to targeted drug therapies. Advances in Genetics 103, pp. 91-118. (10.1016/bs.adgen.2018.11.003)

2018

• Bruning, U. et al. 2018. Impairment of angiogenesis by fatty acid synthase inhibition Involves mTOR malonylation. Cell Metabolism 28(6), pp. 866-880. (10.1016/j.cmet.2018.07.019)
• Johnson, C. E. et al. 2018. Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir−bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death. Oncogene 37, pp. 5913-5925. (10.1038/s41388-018-0381-2)
• McCann, H., Johnson, C., Errington, R., Davies, D. M., Dunlop, E. and Tee, A. 2018. Energy stress-mediated cytotoxicity in tuberous sclerosis complex 2-deficient cells with nelfinavir and mefloquine treatment. Cancers 10(10), pp. -., article number: 375. (10.3390/cancers10100375)
• Murray, J. and Tee, A. 2018. Mechanistic Target of Rapamycin (mTOR) in the cancer setting. Cancers 10(6), pp. 168. (10.3390/cancers10060168)
• Tee, A. 2018. The target of rapamycin and mechanisms of cell growth. International Journal of Molecular Sciences 19(3), pp. 880-892. (10.3390/ijms19030880)
• Rad, E., Murray, J. and Tee, A. 2018. Oncogenic signalling through mechanistic Target Of Rapamycin (mTOR): a driver of metabolic transformation and cancer progression. Cancers 10(1) (10.3390/cancers10010005)

2017

• Johnson, C. E. and Tee, A. R. 2017. Exploiting cancer vulnerabilities: mTOR, autophagy, and homeostatic imbalance. Essays in Biochemistry 61(6), pp. 699-710. (10.1042/EBC20170056)
• Dunlop, E. A., Johnson, C., Wiltshire, M., Errington, R. J. and Tee, A. 2017. Targeting protein homeostasis with nelfinavir/salinomycin dual therapy effectively. Oncotarget (10.18632/oncotarget.16232)

2016

• Tee, A. 2016. The benefits of exploiting rare genetic disorders to better understand human health and disease. Seminars in Cell & Developmental Biology 52, pp. 1-2. (10.1016/j.semcdb.2016.03.007)
• Carroll, B. et al. 2016. Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity. eLife 5, pp. -., article number: e11058. (10.7554/eLife.11058)
• Rad, E. and Tee, A. 2016. Neurofibromatosis type 1: Fundamental insights into cell signalling and cancer. Seminars in Cell & Developmental Biology 52, pp. 39-46. (10.1016/j.semcdb.2016.02.007)
• Tee, A., Sampson, J. R., Pal, D. K. and Bateman, J. M. 2016. The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex. Seminars in Cell and Developmental Biology 52, pp. 12-20. (10.1016/j.semcdb.2016.01.040)

2015

• Upadhyaya, M. et al. 2015. Correlation of copy number changes and gene expression in neurofibromatosis1-associated malignant peripheral nerve sheath tumours [Abstract]. Pediatric Blood and Cancer 62(S4), pp. S152-S152. (10.1002/pbc.25715)
• Zhang, L. et al. 2015. Reversal of pathological features of Graves' orbitopathy by activation of forkhead transcription factors, FOXOs. Journal of Clinical Endocrinology & Metabolism 101(1), pp. 114-122. (10.1210/jc.2015-2932)
• Rad, E., Dodd, K. M., Thomas, L. E., Upadhyaya, M. and Tee, A. 2015. STAT3 and HIF1 signaling drives oncogenic cellular phenotypes in malignant peripheral nerve sheath tumors. Molecular Cancer Research 13(7), pp. 1149. (10.1158/1541-7786.MCR-14-0182)
• Dodd, K. M., Yang, J., Shen, M. H., Sampson, J. R. and Tee, A. R. 2015. mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene 34(17), pp. 2239-2250. (10.1038/onc.2014.164)
• Thomas, L. E. et al. 2015. Evaluation of copy number variation and gene expression in neurofibromatosis type-1-associated malignant peripheral nerve sheath tumours. Human Genomics 9(1), article number: 3. (10.1186/s40246-015-0025-3)

2014

• Dunlop, E. and Tee, A. 2014. mTOR and autophagy: a dynamic relationship governed by nutrients and energy. Seminars in Cell and Developmental Biology 36, pp. 121-129. (10.1016/j.semcdb.2014.08.006)
• Tee, A. 2014. Fundamental for life: mTOR orchestrates developing biological systems. Seminars in Cell & Developmental Biology 36, pp. 66-67. (10.1016/j.semcdb.2014.10.001)
• Johnson, C. et al. 2014. Endoplasmic reticulum stress and cell death in mTORC1-overactive cells is induced by nelfinavir and enhanced by chloroquine. Molecular Oncology 9(3), pp. 675-688. (10.1016/j.molonc.2014.11.005)
• Zhang, L. et al. 2014. Possible targets for nonimmunosuppressive therapy of Graves' orbitopathy. Journal of Clinical Endocrinology & Metabolism 99(7), pp. E1183-E1190. (10.1210/jc.2013-4182)
• Yan, M. et al. 2014. The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation. Journal of Clinical Investigation 124(6), pp. 2640-2650. (10.1172/JCI71749)
• Dunlop, E. et al. 2014. FLCN, a novel autophagy component, interacts with GABARAP and is regulated by ULK1 phosphorylation. Autophagy 10(10), pp. 1749-1760. (10.4161/auto.29640)

2013

• Luijten, M. N. H. et al. 2013. Birt–Hogg–Dubé syndrome is a novel ciliopathy. Human Molecular Genetics 22(21), pp. 4383-4397. (10.1093/hmg/ddt288)
• Zhang, J. et al. 2013. A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS. Nature Cell Biology 15(10), pp. 1186-1195. (10.1038/ncb2822)
• Dhingra, R. et al. 2013. Bidirectional regulation of nuclear factor- B and mammalian target of rapamycin signaling functionally links Bnip3 gene repression and cell survival of ventricular myocytes. Circulation: Heart Failure 6(2), pp. 335-343. (10.1161/CIRCHEARTFAILURE.112.000061)
• Tripathi, D. N., Chowdhury, R., Trudel, L. J., Tee, A., Slack, R. S., Walker, C. L. and Wogan, G. N. 2013. Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1. Proceedings of the National Academy of Sciences of the United States of America 110(32), pp. E2950-E2957. (10.1073/pnas.1307736110)

2012

• Tee, A. and Pause, A. 2012. Birt-Hogg-Dubé: tumour suppressor function and signalling dynamics central to folliculin. Familial Cancer 12(3), pp. 367-372. (10.1007/s10689-012-9576-9)

2011

• Dunlop, E. A., Hunt, D. K., Acosta-Jaquez, H. A., Fingar, D. C. and Tee, A. 2011. ULK1 inhibits mTORC1 signaling, promotes multisite Raptor phosphorylation and hinders substrate binding. Autophagy 7(7), pp. 737-747. (10.4161/auto.7.7.15491)
• Dunlop, E. A. et al. 2011. Determining the pathogenicity of patient-derived TSC2 mutations by functional characterization and clinical evidence. European Journal of Human Genetics 19(7), pp. 789-795. (10.1038/ejhg.2011.38)
• Preston, R. S. et al. 2011. Absence of the Birt-Hogg-Dubé gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility. Oncogene 30(10), pp. 1159-1173. (10.1038/onc.2010.497)

2010

• Scott, C. L., Walker, D. J., Cwiklinski, E., Tait, C., Tee, A. and Land, S. C. 2010. Control of HIF-1α and vascular signaling in fetal lung involves cross talk between mTORC1 and the FGF-10/FGFR2b/Spry2 airway branching periodicity clock. AJP: Lung Cellular and Molecular Physiology 299(4), pp. L455-L471. (10.1152/ajplung.00348.2009)
• Soliman, G. A., Acosta-Jaquez, H. A., Dunlop, E. A., Ekim, B., Maj, N. E., Tee, A. and Fingar, D. C. 2010. mTOR Ser-2481 Autophosphorylation Monitors mTORC-specific Catalytic Activity and Clarifies Rapamycin Mechanism of Action. Journal of Biological Chemistry 285(11), pp. 7866-7879. (10.1074/jbc.M109.096222)

2009

• Dunlop, E. A., Dodd, K. M., Seymour, L. A. and Tee, A. 2009. Mammalian target of rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein-protein interactions for substrate recognition. Cellular Signalling 21(7), pp. 1073-1084. (10.1016/j.cellsig.2009.02.024)
• Dunlop, E. A. and Tee, A. 2009. Mammalian target of rapamycin complex 1: Signalling inputs, substrates and feedback mechanisms. Cellular Signalling 21(6), pp. 827-835. (10.1016/j.cellsig.2009.01.012)
• Tee, A., Sampson, J. R. and Cheadle, J. P. 2009. Tuberous sclerosis complex. In: Schwab, M. ed. Encyclopedia of Cancer. 2nd ed. Springer
• Baird, F. E., Bett, K. J., MacLean, C., Tee, A., Hundal, H. S. and Taylor, P. M. 2009. Tertiary active transport of amino acids reconstituted by coexpression of System A and L transporters in Xenopus oocytes. American Journal of Physiology. Endocrinology and Metabolism 297(3), pp. E822-E829. (10.1152/ajpendo.00330.2009)

2003

• Tee, A., Manning, B. D., Roux, P. P., Cantley, L. C. and Blenis, J. 2003. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Current Biology 13(15), pp. 1259-1268. (10.1016/S0960-9822(03)00506-2)

2002

• Tee, A., Fingar, D. C., Manning, B. D., Kwiatkowski, D. J., Cantley, L. C. and Blenis, J. 2002. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proceedings of the National Academy of Sciences 99(21), pp. 13571-13576. (10.1073/pnas.202476899)
• Manning, B. D., Tee, A., Logsdon, M. N., Blenis, J. and Cantley, L. C. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Molecular Cell 10(1), pp. 151-162. (10.1016/S1097-2765(02)00568-3)
• Tee, A. and Proud, C. G. 2002. Caspase cleavage of initiation factor 4E-binding protein 1 yields a dominant inhibitor of cap-dependent translation and reveals a novel regulatory motif. Molecular and Cellular Biology 22(6), pp. 1674-1683. (10.1128/MCB.22.6.1674-1683.2002)